Celecoxib reduces pulmonary inflammation but not lung tumorigenesis in mice

Carcinogenesis

Volumn 23, Issue 10, 2002, Pages 1653-1660

  Kisley, Lori R ^a   Barrett, Bradley S ^a   Dwyer Nield, Lori D ^a   Bauer, Alison K ^a   Thompson, David C ^a   Malkinson, Alvin M ^a  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [3 [5 (4 FLUOROPHENOXY) 2 FURYL] 1 METHYL 2 PROPYNYL] 1 HYDROXYUREA; 3 METHYLCHOLANTHRENE; ACETYLSALICYLIC ACID; BUDESONIDE; BUTYLCRESOL; CELECOXIB; CORTICOSTERONE; CYCLOOXYGENASE 2 INHIBITOR; DEXAMETHASONE; GLUCOCORTICOID; ICOSANOID; INDOMETACIN; LIPOXYGENASE; LIPOXYGENASE INHIBITOR; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; NORDIHYDROGUAIARETIC ACID; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; SULINDAC; URETHAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; CELL INFILTRATION; CLINICAL PROTOCOL; COLON CANCER; CONTROLLED STUDY; CYTOSOL; DRUG EFFICACY; HIGH RISK POPULATION; LUNG CANCER; LUNG CARCINOGENESIS; LUNG TUMOR; MACROPHAGE; MALE; MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; PROTEIN TRANSPORT;

EID: 0036799842     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/23.10.1653     Document Type: Article

References (61)

1. Greenlee, R.T., Hill-Harmon, M.B., Murray, T. and Thun, M. (2001) Cancer statistics 2001. CA Cancer J. Clin., 51 15-36.
2. Gazdar, A.F. and Linnoila, R.I. (1988) The pathology of lung cancer-changing concepts and newer diagnostic techniques. Semin. Oncol. 15 215-225.
3. Lau, C.L. D'Amico, T.A. and Harpole, D.H. Jr (2000) Clinical and molecular prognostic factors and models for non-small cell lung cancer. In Pass,H.I., Mitchell J.B., Johnson,D.H., Turrisi A.T. and Minna,J.D. (eds) Lung Cancer: Principles and Practice. Lippincott Williams & Wilkins Philadelphia, PA, pp. 602-611.
4. Carney, D.N. (2002) Lung cancer-time to move on from chemotherapy. N. Engl. J. Med., 346, 126-128.
5. DuBois, R.N., Giardiello, F.M. and Smalley, W.E. (1996) Nonsteroidal antiinflammatory drugs, eicosanoids, and colorectal cancer prevention. Gastroenterol. Clin. North Am., 25, 773-791.
6. Oshima, M., Dinchuk, J.E., Kargman, S.L., Oshima, H., Hancock, B., Kwong, E., Trzaskos, J.M., Evans, J.F. and Taketo, M.M. (1996) Suppression of intestinal polyposis in Ape delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87, 803-809.
7. Kawamori, T., Rao, C.V., Seibert, K. and Reddy, B.S. (1998) Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res., 58, 409-412.
8. Farrow, D.C., Vaughan, T.L., Hansten, P.D. et al. (1998) Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol. Biomarkers Prev., 7, 97-102.
9. Egan, K.M., Stampfer, M.J., Giovannucci, E., Rosner, B.A. and Colditz, G.A. (1996) Prospective study of regular aspirin use and the risk of breast cancer. J. Natl Cancer Inst., 88, 988-993.
10. Malkinson, A.M. (1992) Primary lung tumors in mice: an experimentally manipulable model of human adenocarcinoma. Cancer Res., 52, 2670s-2676s.
11. Malkinson, A.M. (1998) Molecular comparison of human and mouse pulmonary adenocarcinomas. Exp. Lung Res., 24, 541-555.
12. Malkinson, A.M. (2001) Primary lung tumors in mice as an aid for understanding, preventing, and treating human adenocarcinoma of the lung. Lung Cancer, 32, 265-279.
13. Miller, A.C., Dwyer, L.D., Auerbach, C.E., Miley, F.B., Dinsdale, D., and Malkinson, A.M. (1994) Strain-related differences in the pneumotoxic effects of chronically administered butylated hydroxytoluene on protein kinase C and calpain. Toxicology, 90, 141-159.
14. Bauer, A.K., Dwyer-Nield, L.D. and Malkinson, A.M. (2000) High cyclooxygenase 1 (COX-1) and cyclooxygetrase 2 (COX-2) contents in mouse lung tumors. Carcinogenesis, 21, 543-550.
15. Bauer, A.K., Dwyer-Nield, L.D., Keil, K., Koski, K. and Malkinson, A.M. (2001) Butylated hydroxytoluene (BHT) induction of pulmonary inflammation: a role in tumor promotion. Exp. Lung Res., 27, 197-216.
16. Bauer, A.K., Dwyer-Nield, L.D., Hankin, J.A., Murphy, R.C. and Malkinson, A.M. (2001) The lung tumor promoter, butylated hydroxytoluene (BHT), causes chronic inflammation in promotion-sensitive BALB/cByJ mice but not in promotion-resistant CXB4 mice. Toxicology, 169, 1-15.
17. Cohen, B.H., Diamond, E.L., Graves, C.G., Kreiss, P., LevyD. A., Menkes, H.A., Permutt, S., Quaskey, S. and Tockman, M.S. (1977) A common familial component in lung cancer and chronic obstructive pulmonary disease. Lancet, 2, 523-526.
18. Tockman, M.S., Anthonisen, N.R., Wright, E.C. and Donithan, M.G. (1987) Airways obstruction and the risk for lung cancer. Ann. Intern. Med., 106, 512-518.
19. Wardlaw, S.A., March, T.H. and Belinsky, S.A. (2000) Cyclooxygenase-2 expression is abundant in alveolar type II cells in lung cancer-sensitive mouse strains and in premalignant lesions. Carcinogenesis, 21, 1371-1377.
20. Yao, R., Rioux, N., Castonguay, A. and You, M. (2000) Inhibition of COX-2 and induction of apoptosis: two determinants of nonsteroidal antiinflammatory drugs' chemopreventive efficacies in mouse lung tumorigenesis. Exp. Lung Res., 26, 731-742.
21. Moody, T.W, Leyton, J., Zakowicz, H. et al. (2001) Indomethacin reduces lung adenoma number in A/J mice. Anticancer Res., 21, 1749-1755.
22. Duperron, C. and Castonguay, A. (1997) Chemopreventive efficacies of aspirin and sulindac against lung tumorigenesis in A/J mice. Carcinogenesis, 18, 1001-1006.
23. Rioux, N. and Castonguay, A. (1998) Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398. Cancer Res., 58, 5354-5360.
24. Malkinson, A.M., Koski, K.M., Evans, W.A. and Festing, M.F. (1997) Butylated hydroxytoluene exposure is necessary to induce lung tumors in BALB mice treated with 3-methylcholanthrene. Cancer Res., 57, 2832-2834.
25. Gressani, K.M., Leone-Kabler, S., O'Sullivan, M.G., Case, L.D., Malkinson, A.M. and Miller, M.S. (1999) Strain-dependent lung tumor formation in mice transplacentally exposed to 3-methylcholanthrene and post-natally exposed to butylated hydroxytoluene. Carcinogenesis, 20, 2159-2165.
26. Gopalakrishna, R., Gundimeda, U. and Chen, Z.-H. (1998) Protein kinase C modulation by tobacco tumor promoters. In Kane,M.A. and Bunn,P.A. Jr (eds) Biology of Lung Cancer. Marcel Dekker, Inc., New York, Vol. 122, pp.413-40.
27. Thompson, J.A., Malkinson, A.M., Wand, M.D., Mastovich, S.L., Mead, E.W., Schullek, K.M. and Laudenschlager W.G. (1987) Oxidative metabolism of butylated hydroxytoluene by hepatic and pulmonary microsomes from rats and mice. Drug Metab. Dispos., 15, 833-840.
28. Adamson,I.Y., Bowden,D.H., Cote,M.G. and Witschi,H. (1977) Lung injury induced by butylated hydroxytoluene: cytodynamic and biochemical studies in mice. Lab. Invest., 36, 26-32.
29. Marks,F., Furstenberger,G. and Muller-Decker,K. (1999) Metabolic targets of cancer chemoprevention: interruption of tumor development by inhibitors of arachidonic acid metabolism. Recent Results Cancer Res., 151, 45-67.
30. Uefuji,K., Ichikura,T. and Mochizuki,H. (2000) Cyclooxygenase-2 expression is related to prostaglandin biosynthesis and angiogenesis in human gastric cancer. Clin. Cancer Res., 6, 135-138.
31. Jacoby,R.F., Seibert,K., Cole,C.E., Kelloff,G. and Lubet,R.A. (2000) The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res., 60, 5040-5044.
32. Masferrer,J.L., Leahy,K.M., Koki,A.T., Zweifel,B.S., Settle,S.L., Woerner,B.M., Edwards,D.A., Flickinger,A.G., Moore,R.J. and Seibert,K. (2000) Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res., 60, 1306-1311.
33. Reddy,B.S., Hirose,Y., Lubet,R., Steele,V., Kelloff,G., Paulson,S., Seibert,K. and Rao,C.V. (2000) Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res., 60, 293-297.
34. Paulson,S.K., Zhang,J.Y., Breau,A.P. et al. (2000) Pharmacokinetics, tissue distribution, metabolism, and excretion of celecoxib in rats. Drug Metab. Dispos., 28, 514-521.
35. Malkinson,A.M. (1979) Prevention of butylated hydroxytoluene-induced lung damage in mice by cedar terpene administration. Toxicol. Appl. Pharmacol., 49, 551-560.
36. Hecht,S.S., Morse,M.A., Eklind,K.I. and Chung,F.L. (1991) A/J mouse lung tumorigenesis by the tobacco-specific nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and its inhibition by arylalkyl isothiocyanates. Exp. Lung Res., 17, 501-511.
37. FitzGerald,G.A. and Patrono,C. (2001) The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med., 345, 433-442.
38. Perazella,M.A. and Tray,K. (2001) Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional nonsteroidal antiinflammatory drugs. Am. J. Med., 111, 64-67.
39. Morham,S.G., Langenbach,R., Loftin,C.D. et al. (1995) Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell, 83, 473-482.
40. Fischer,S.M., Lo,H.H., Gordon,G.B., Seibert,K., Kelloff,G., Lubet,R.A. and Conti,C.J. (1999) Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol. Carcinogen., 25, 231-240.
41. Voelkel,N.F., Tuder,R.M., Wade,K., Hoper,M., Lepley,R.A., Goulet,J.L., Koller,B.H. and Fitzpatrick,F. (1996) Inhibition of 5-lipoxygenase-activating protein (FLAP) reduces pulmonary vascular reactivity and pulmonary hypertension in hypoxic rats. J. Clin. Invest, 97, 2491-2498.
42. Brock,T.G., Maydanski,E., McNish,R.W. and Peters-Golden,M. (2001) Colocalization of leukotriene α4 hydrolase with 5-lipoxygenase in nuclei of alveolar macrophages and rat basophilic leukemia cells but not neutrophils. J. Biol. Chem., 276, 35071-35077.
43. Steele,V.E., Holmes,C.A., Hawk,E.T., Kopelovich,L., Lubet,R.A., Crowell,J.A., Sigman,C.C. and Kelloff,G.J. (1999) Lipoxygenase inhibitors as potential cancer chemopreventives. Cancer Epidemiol. Biomarkers Prev., 8, 467-483.
44. Droms,K.A., Fernandez,C.A., Thaete,L.G. and Malkinson,A.M. (1988) Effects of adrenalectomy and corticosterone administration on mouse lung tumor susceptibility and histogenesis. J. Natl Cancer Inst., 80, 365-369.
45. Oomen,L.C., van der Valk,M.A., Hart,A.A. and Demant,P. (1989) Glucocorticoid hormone effect on transplacental carcinogenesis and lung differentiation: influence of histocompatibility-2 complex. J. Natl Cancer Inst., 81, 512-517.
46. Wattenberg,L.W. and Estensen,R.D. (1996) Chemopreventive effects of myo-mositol and dexamethasone on benzo[a]pyrene and 4-(methyl-nitrosoamino)-1-(3-pyridyl)-1-butanone-induced pulmonary carcinogenesis in female A/J mice. Cancer Res., 56, 5132-5135.
47. Witschi,H., Espiritu,I. and Uyeminami,D. (1999) Chemoprevention of tobacco smoke-induced lung tumors in A/J strain mice with dietary myoinositol and dexamethasone. Carcinogenesis, 20, 1375-1378.
48. Gunning,W.T., Kramer,P.M., Lubet,R.A., Steele,V.E. and Pereira,M.A. (2000) Chemoprevention of vinyl carbamate-induced lung tumors in strain A mice. Exp. Lung Res., 26, 757-772.
49. Lubet,R.A., Zhang,Z., Wiseman,R.W. and You,M. (2000) Use of p53 transgenic mice in the development of cancer models for multiple purposes. Exp. Lung Res., 26, 581-593.
50. Wattenberg,L.W., Wiedmann,T.S., Estensen,R.D., Zimmerman,C.L., Steele,V.E. and Kelloff,G.J. (1997) Chemoprevention of pulmonary carcinogenesis by aerosolized budesonide in female A/J mice. Cancer Res., 57, 5489-5492.
51. Adriaenssens,P.I., Sivarajah,K., Boorman,G.A., Eling,T.E. and Anderson,M.W. (1983) Effect of aspirin and indomethacin on the formation of benzo(a)pyrene-induced pulmonary adenomas and DNA adducts in A/HeJ mice. Cancer Res., 43, 4762-4767.
52. Castonguay,A., Rioux,N., Duperron,C. and Jalbert,G. (1998) Inhibition of lung tumorigenesis by NSAIDS: a working hypothesis. Exp. Lung Res., 24, 605-615.
53. Malkinson,A.M., Koski,K.M., Dwyer-Nield,L.D., Rice,P.L., Rioux,N., Castonguay,A., Ahnen,D.J., Thompson,H., Pamukcu,R. and Piazza,G.A. (1998) Inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced mouse lung tumor formation by FGN-1 (sulindac sulfone). Carcinogenesis, 19, 1353-1356.
54. Geraci,M.W., Gao,B., Shepherd,D.C., Moore,M.D., Westcott,J.Y., Fagan,K.A., Alger,L.A., Tuder,R.M. and Voelkel,N.F. (1999) Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension. J. Clin. Invest., 103, 1509-1515.
55. Keith,R.L., Miller,Y.E., Hoshikawa,Y., Moore,M.D., Gesell,T.L., Gao,B., Malkinson,A.M., Golpon,H.A., Nemenoff,R.A. and Geraci,M.W. (2002) Prostacyclin sythase overexpression prevents mouse lung carcinogenesis. Cancer Res., 62, 734-740.
56. Tegeder,I., Pfeilsehifter,J. and Geisslinger,G. (2001) Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J., 15, 2057-2072.
57. Jaradat,M.S., Wongsud,B., Phornchirasilp,S., Rangwala,S.M., Shams,G., Sutton,M., Romstedt,K.J., Noonan,D.J. and Feller,D.R. (2001) Activation of peroxisome proliferator-activated receptor isoforms and inhibition of prostaglandin H(2) synthases by ibuprofen, naproxen, and indomethacin. Biochem. Pharmacol., 62, 1587-1595.
58. Grilli,M., Pizzi,M., Memo,M. and Spano,P. (1996) Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation. Science, 274, 1383-1385.
59. Inoue, K., Kawahito, Y., Tsubouchi, Y., Yamada, R., Kohno, M., Hosokawa, Y., Katoh,D., Bishop-Bailey,D., Hla,T. and Sano,H. (2001) Expression of peroxisome proliferator-activated receptor (PPAR)-gamma in human lung cancer. Anticancer Res., 21, 2471-2476.
60. Piazza,G.A., Rahm,A.K., Finn,T.S., Fryer,B.H., Li,H., Stoumen,A.L., Pamukcu,R. and Ahnen,D.J. (1997) Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res., 57, 2452-2459.
61. Piazza,G.A., Alberts,D.S., Hixson,L.J. et al. (1997) Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res., 57, 2909-2915.